Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788039 | 0.83 | TSHR (0.38) | MRGPRX4TSHRPTGDR2 | |
| SCHEMBL7175438 | 0.83 | PTGDR2 (0.39) | TSHRPTGDR2 | |
| SCHEMBL22946143 | 0.83 | TSHR (0.41) | TSHRPTGDR2 | |
| SCHEMBL11455772 | 0.82 | CSNK2A1 (0.43) | CSNK2A1TSHR | |
| SCHEMBL21431038 | 0.82 | TSHR (0.40) | TSHRPTGDR2 | |
| SCHEMBL6783812 | 0.81 | TSHR (0.39) | TSHRPTGDR2 | |
| SCHEMBL30954310 | 0.81 | TSHR (0.36) | TSHRPTGDR2 | |
| SCHEMBL5274226 | 0.80 | TSHR (0.41) | MRGPRX4TSHRPTGDR2 | |
| SCHEMBL1714808 | 0.80 | TSHR (0.39) | MRGPRX4TSHRPTGDR2 | |
| SCHEMBL8317291 | 0.80 | CSNK2A1 (0.44) | CSNK2A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007120012-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2007-10-25 | — | — | WO | disclosed |
| US-20040092754-A1 | Derivatives of 4-(trifluoromethyl)-phenol and 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether and method for producing the same | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1309531-A1 | DERIVATIVES OF 4-(TRIFLUOROMETHYL)-PHENOL AND 4-(TRIFLUOROMETHYLPHENYL)-2-(TETRAHYDROPYRANYL) ETHER AND METHOD FOR PRODUCING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014250-A1 | DERIVATIVES OF 4-(TRIFLUOROMETHYL)-PHENOL AND 4-(TRIFLUOROMETHYLPHENYL)-2-(TETRAHYDROPYRANYL) ETHER AND METHOD FOR PRODUCING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092754-A1 | Derivatives of 4-(trifluoromethyl)-phenol and 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether and method for producing the same | EPX, CYP4X1, EPHX2 | MRGPRX4 669/4885CSNK2A1 1595/4885TSHR 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.